Table 3.
All-cause mortality for all patients, with types of infections and their resistance pattern.
| Number of Patients | 14-Day All-Cause Mortality | 28-Day All-Cause Mortality | Organisms (Number of Cases) |
Pertinent Diagnosis/Clinical Course | Cefiderocol Susceptibility (Number of Cases) |
Meropenem Susceptibility (Number of Cases) | Ceftazidime/Avibactam Susceptibility (Number of Cases) |
Ceftolozane/Tazobactam Susceptibility (Number of Cases) |
|
|---|---|---|---|---|---|---|---|---|---|
| Patients receiving cefiderocol | 22 | 1 (4.5%) | 3 (13.6%) | ||||||
| Lower respiratory tract infection | 6 | 1 (16.7%) | 1 (16.7%) | CRAB (2) DTR-P (4) |
HABP (4) VABP (2) |
S (3) I (1) R (1) N/A (1) |
R (6) | N/A (4) R (2) |
S (1) I (2) R (1) N/A (2) |
| Bloodstream infection | 3 | 0 (0%) | 0 (0%) | CRAB (1) DTR-P (2) |
S (2) N/A (1) |
R (3) | N/A (2) R (1) |
S (1) I (1) N/A (1) |
|
| cUTI | 2 | 0 (0%) | 0 (0%) | DTR-P (2) | S (1) N/A (1) |
R (3) | N/A (2) | S (2) | |
| Other sites (intra-abdominal, orbital, and buccal abscess, sacral, lower extremity and facial wound) | 11 | 0 (0%) | 2 (18.2%) | ||||||
| Intrabdominal abscess | CRAB (2) DTR-P (1) |
One patient underwent IR guided drainage 6 days prior to starting cefiderocol | S (3) | R (3) | N/A (2) R (1) |
S (1) N/A (2) |
|||
| Orbital abscess | CRAB (1) | No drainage or surgery performed | S (1) | R (1) | N/A (1) | N/A (1) | |||
| Buccal abscess | DTR-P (1) | I&D performed 1 day prior to starting cefiderocol | S (1) | R (1) | R(1) | I (1) | |||
| Facial wound | DTR-P (1) | Debridement performed 13 days prior to starting cefiderocol | S (1) | R (1) | R (1) | I (1) | |||
| Mid-sternal wound | CRAB (1) | Washout and debridement performed 3 days after starting cefiderocol | S (1) | R (1) | N/A (1) | N/A (1) | |||
| Lower extremity wound | CRAB (1) DTR-P (1) |
Debridement performed in both patients, 2 days and 3 days before starting cefiderocol, respectively | N/A (1) R (1) |
R (2) | N/A (2) | N/A (1) R (1) |
|||
| Osteomyelitis of left lower extremity digits | DTR-P (1) | Debridement of ulcer and resection of left foot first and second ray performed 2 days after starting cefiderocol | R (1) | R (1) | R (1) | R (1) | |||
| Sacral wound | DTR-P (1) | Debridement performed 4 days prior to starting cefiderocol | R (1) | R (1) | R (1) | S (1) |
S: susceptible, I: intermediate, R: resistant, N/A: not available, I&D: incision and drainage.